À la recherche des patientes présentant un cancer HER2/neu positif : analyse rétrospective
Bibliographic record
Abstract
Resume Objectif : Evaluer le nombre de patientes qui pourraient beneficier du trastuzumab comme traitement adjuvant du cancer du sein durant la periode d’avril 2004 a juin 2005 a l’Hopital Charles LeMoyne. Methodologie : Etude retrospective descriptive d’observation des dossiers des patientes ayant recu un diagnostic de cancer du sein pendant la periode d’avril 2004 a juin 2005. Resultats : Deux cent soixante-trois (263) patientes ont recu un diagnostic de cancer du sein entre avril 2004 et juin 2005. Cent quatre (104) patientes repondaient aux criteres d’inclusion et chez 18,3 % d’entre elles (19 cas sur 104), on retrouve une amplification de l’oncogene HER2. Ces 19 cas, dont 14 etaient traites en adjuvant et cinq (5), en neo-adjuvant, correspondent a 7,22 % de la population a l’etude (19 patientes sur 263). Ce sont donc ces femmes qui pourront beneficier de la nouvelle utilisation du trastuzumab. Conclusion : Une proportion de 7,22 % des nouveaux cas de cancer du sein diagnostiques depuis la derniere annee pourra etre traitee avec le trastuzumab en adjuvant a l’Hopital Charles LeMoyne. Force est d’admettre que cet anticorps monoclonal, au prix d’environ 50 000 $ par annee et par patiente, necessite une attention particuliere. Cette etude nous permet d’evaluer les besoins associes a cette nouvelle utilisation, en plus de prevoir et d’extrapoler le budget necessaire pour les annees futures. Abstract Objective: To evaluate the number of Hopital Charles-Lemoyne breast cancer patients that would benefit from adjuvant treatment with trastuzumab. Methods: Using an observational and retrospective study design, we reviewed charts of patients diagnosed with breast cancer during the period of April 2004 to June 2005. Results: 263 patients were diagnosed with breast cancer between April 2004 and June 2005. 104 patients fit the inclusion criteria. Amplification of the HER2 oncogene was found in 18.3 % of these patients (19 patients out of 104). Of these 19 patients, 14 were treated in the adjuvant setting and 5 were treated in the neoadjuvant setting, corresponding to 7.22% of the study population (19 patients out of 263). Therefore, it is these women that would benefit from treatment with trastuzumab. Conclusion: In 2005, 7.22% of newly diagnosed Hopital Charles-Lemoyne breast cancer cases were treated with adjuvant trastuzumab. However, it must be considered that this monoclonal antibody costs approximately $50, 0000 per year per patient. This study makes it possible to evaluate the changes involved with a new indication for a drug, as well as to evaluate budgetary projections needed for the future. Key Words: trastuzumab, HER2/neu, adjuvant, breast cancer, tumor.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.009 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".